Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07116473) titled 'To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)' on Aug. 7.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Eidos Therapeutics, a BridgeBio company
Condition:
Amyloidosis in Transthyretin (TTR)
Amyloidosis, Familial
Amyloid Cardiomyopathy
Amyloid Cardiomyopathy, Transthyretin-Related
Amyloidogenic Transthyretin (ATTR) Amyloidosis
Heart Disease
Cardiomyopathies
Amyloidosis, Hereditary, Transthyretin-Related
Polyn...